Research Study2024

Implementation of a mobile health clinic framework for HCV screening and treatment

Rennert, Lior; Howard, Kerry A.; Kickham, Caitlin M.; Gezer, Fatih; Coleman, Ashley; Roth, Prerana; Boswell, Kristie; Gimbel, Ronald W.; Litwin, Alain H.

Infectious Disease

Why this matters

Hepatitis C screening has limited value unless patients can also move through treatment. Across 607 people screened at 31 South Carolina locations, 15.5 percent tested positive, 49.6 percent of those started treatment, and 86 percent of those who started completed it.

Authors
Rennert, Lior; Howard, Kerry A.; Kickham, Caitlin M.; Gezer, Fatih; Coleman, Ashley; Roth, Prerana; Boswell, Kristie; Gimbel, Ronald W.; Litwin, Alain H.
Journal
The Lancet Regional Health - Americas
Year
2024
Study design
Retrospective Cohort
Setting
Rural
Population
Low-Income/Uninsured; People Who Use Drugs
Outcome domain
Clinical Outcomes
Type of organization
Academic

Abstract

BACKGROUND: Although treatment for Hepatitis C Virus (HCV) is effective, individuals face access barriers. The utility of mobile health clinics (MHC), effective mechanisms for providing healthcare to underserved populations, is understudied for HCV-related interventions. We aimed to describe implementation of, and factors associated with, screening and treatment via MHCs. METHODS: Clemson Rural Health implemented a novel MHC program to reach and treat populations at-risk for HCV with a focus on care for uninsured individuals. We examined HCV screening and treatment initiation/completion indicators between May 2021 and January 2023. FINDINGS: Among 607 individuals screened across 31 locations, 94 (15.5%) tested positive via antibody and viral load testing. Treatment initiation and completion rates were 49.6% and 86.0%, respectively. Among those screened, the majority were male (57.5%), White (61.3%; Black/Hispanic: 28.2%/7.7%), and without personal vehicle as primary transportation mode (54.4%). Injection drug use (IDU) was 27.2% and uninsured rate was 42.8%. Compared to HCV-negative, those infected included more individuals aged 30-44 (52.1% vs. 36.4%, p = 0.023), male (70.2% vs. 55.2%, p = 0.009), White (78.5% vs. 60.2%, p < 0.0001), without personal vehicle (58.5% vs. 43.5%, p = 0.028), IDU (83.7% vs. 21.0%, p < 0.0001), and uninsured (61.2% vs. 48.8%, p = 0.050). Uninsured rates were higher among those initiating compared to not initiating treatment (74.5% vs. 45.3%, p = 0.004). INTERPRETATION: The MHC framework successfully reaching its target population: at-risk individuals with access barriers to healthcare. The high HCV screening and treatment initiation/completion rates demonstrate the utility of MHCs as effective and acceptable intervention settings among historically difficult-to-treat populations.

Cite this study:Rennert, Lior; Howard, Kerry A.; Kickham, Caitlin M.; Gezer, Fatih; Coleman, Ashley; Roth, Prerana; Boswell, Kristie; Gimbel, Ronald W.; Litwin, Alain H. (2024). Implementation of a mobile health clinic framework for HCV screening and treatment. The Lancet Regional Health - Americas. https://doi.org/10.1016/j.lana.2023.100648
Metadata curated by Mission Mobile Medical. Full text is available from the publisher via the DOI link above.